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Abstract
We present a 3D multi-cell simulation of a generic simplification of vascular tumor growth which can be easily extended and
adapted to describe more specific vascular tumor types and host tissues. Initially, tumor cells proliferate as they take up the
oxygen which the pre-existing vasculature supplies. The tumor grows exponentially. When the oxygen level drops below a
threshold, the tumor cells become hypoxic and start secreting pro-angiogenic factors. At this stage, the tumor reaches a
maximum diameter characteristic of an avascular tumor spheroid. The endothelial cells in the pre-existing vasculature
respond to the pro-angiogenic factors both by chemotaxing towards higher concentrations of pro-angiogenic factors and
by forming new blood vessels via angiogenesis. The tumor-induced vasculature increases the growth rate of the resulting
vascularized solid tumor compared to an avascular tumor, allowing the tumor to grow beyond the spheroid in these linear-
growth phases. First, in the linear-spherical phase of growth, the tumor remains spherical while its volume increases.
Second, in the linear-cylindrical phase of growth the tumor elongates into a cylinder. Finally, in the linear-sheet phase of
growth, tumor growth accelerates as the tumor changes from cylindrical to paddle-shaped. Substantial periods during
which the tumor grows slowly or not at all separate the exponential from the linear-spherical and the linear-spherical from
the linear-cylindrical growth phases. In contrast to other simulations in which avascular tumors remain spherical, our
simulated avascular tumors form cylinders following the blood vessels, leading to a different distribution of hypoxic cells
within the tumor. Our simulations cover time periods which are long enough to produce a range of biologically reasonable
complex morphologies, allowing us to study how tumor-induced angiogenesis affects the growth rate, size and
morphology of simulated tumors.
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Introduction
Biology Background
The development of a primary solid tumor starts from a single
cell that proliferates in an inappropriate manner, dividing
repeatedly to form a cluster of tumor cells. Nutrient and waste
diffusion lengths limit the size of such avascular tumor spheroids to
about 1 mm [1]. The central region of the spheroid becomes
necrotic, with a surrounding layer of cells whose hypoxia triggers a
cascade of hypoxia-inducible factor-1 (HIF-1) and vascular-
endothelial-growth-factor (VEGF)-mediated signaling events that
initiate tumor vascularization by promoting growth and extension
(angiogenesis) of nearby blood vessels [2]. This general sequence
occurs in many types of tumors. Vascularized tumors are able to
grow to a much larger size than spheroids and are more likely to
spread and metastasize using blood vessels as pathways for
invasion [3].
Both fetal and adult angiogenesis is primarily a response to
hypoxia [2,4–7]. In adults, angiogenesis plays key roles during
tissue repair and remodeling, e.g. during wound healing and
expansion of tissues during the female reproductive cycle.
The level of HIF-1a DNA-binding activity in the nucleus varies
exponentially with oxygen tension over the physiological range in
mammalian cells [8]. Cells exposed to hypoxic conditions
accumulate activated HIF-1a in their nuclei in less than 2 minutes
[9]. HIF-1a changes the expression levels of numerous hypoxia-
dependent genes including those responsible for oxygen transport,
vascular regulation, angiogenesis, glucose uptake, and glycolysis
(reviewed in [10]). HIF activation also upregulates key angiogen-
esis regulatory signaling molecules including VEGF-A and its
receptors VEGFR-1 and VEGFR-2 [2]. VEGF-A has diffusive,
ECM-bound, and semi-ECM-bound isoforms which differ in
weight and heparin-binding affinity [11]. Tumors secreting
different VEGF-A isoforms induce the formation of morpholog-
ically different neo-vascular beds [12].
Endothelial cells form two distinct types which respond
differently to VEGF-A. Non-dividing tip cells form filopodia and
migrate towards sources of VEGF-A, while non-migrating stalk cells
proliferate but do not form filopodia. [13–15]. Two cell types are
functionally necessary because if every endothelial cell were a tip
cell, the vessels would disintegrate, while uniform division of stalk
cells would fail to form vessels in the correct pattern [13,14].
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stabilization of nascent blood vessels (see [16,17] for reviews).
Formation of cell-cell adhesion junctions via cadherins like VE-
cadherin inhibits the chemotaxis response of endothelial cells to
VEGF-A at endothelial cell-endothelial cell boundaries (contact-
inhibited chemotaxis) and increases the stability of those boundaries
[18]. The growth rate of cultured endothelial cells decreases as the
area of VE-cadherin junctions increases (contact inhibition of
growth)[19].
Normal new blood vessels and tumor-induced blood vessels
differ greatly in morphology and function. Normal new vessels
recruit pericytes and vascular smooth-muscle cells to sites adjacent
to the endothelial cells to stabilize the vessel [20]. Tumor-induced
blood vessels often lack a hierarchical arrangement and have
irregular diameters, high tortuosity, random branching, and
defective endothelial barrier function [20–22].
Computational Background
Because of the range of scales involved in cancer biology, cancer
simulations employ a wide range of techniques depending on their
biological focus. Standard partial-differential-equation (PDE)
continuum models include scales down to the grid size used to
solve the equations. Continuum multi-grid and adaptive-mesh
techniques can cover scales from 102 mm to 10 cm. Hybrid
models, which use cellular automata, agent-based or multi-cell
techniques to represent individual cells and continuum PDEs to
represent diffusion of molecules, can capture more detail than
continuum models spanning scales from microns to millimeters
(for comprehensive reviews of mathematical models of tumor-
growth and angiogenesis see [23–27] and references therein).
Zheng et al. [28] have used an adaptive finite-element/level-set
method to model solid tumor growth in combination with
Anderson and Chaplain’s hybrid model of angiogenesis [24].
Zheng’s model treats tumor cells as a viscous fluid flowing through
a porous medium obeying the Darcy-Stokes law. Zheng et al. have
shown that both diffusional instability (competition of growth and
surface tension) and co-option of the new anastomosed capillaries
may be key glioma invasion mechanisms. Frieboes et al. [29] have
used Zheng’s level-set method in combination with Plank and
Sleeman’s hybrid continuum-discrete [30], lattice-free model of
tumor angiogenesis to model the physiology and evolution of
glioma neovasculature in 3D. Frieboes et al’s model allowed them
to correlate measurable tumor microenvironment parameters to
cell phenotypes and potentially to tumor-scale growth and
invasion. Cristini et al. [31] have also developed a continuum
model of solid avascular tumors using a mixture model obeying
Cahn-Hilliard-type equations. Cristini et al. found that taxis of
tumor cells up gradients of nutrient produces fingering instabilities,
especially when tumor cell proliferation is slow.
The effects of blood flow on vascular remodeling and tumor
growth have been extensively studied by Owen et al. [32], Alarcon
et al. [33], Bartha and Rieger [34], Welter et al. [35], McDougall
et al. [36], Stephanou et al. [37,38], Pries et al. [39–42] and
Macklin et al. [26]. Other vasculature and transport-related effects
remain to be studied [43], for example how tumor cells interact
with endothelial cells and enter and exit the blood stream (intra/
extravasation) and spread to other organs (metastasis) via blood
vessels. The simple model we present in this initial paper neglects
the crucial effects of detailed transport due to blood flow and the
effects of flow-induced vascular remodeling. We discuss some of
the resulting artifacts and missing behaviors below.
Because the Glazier-Graner-Hogeweg model (GGH, also known
as the Cellular Potts Model, CPM) [44–46] handles cell-cell and
cell-ECM adhesion and cell motility more naturally than many
other modeling methods, GGH simulations may provide addi-
tional insight into tumor growth and the complex roles of
angiogenesis. Poplawski et al. [47] developed a GGH simulation
of avascular tumor based on Anderson’s model [48] to study the
effects of adhesion and nutrient transport on the morphology of
avascular tumors. Poplawski et al. found that nutrient-deprived
tumors are generally more invasive and that high tumor-ECM
surface tension changes seaweed-like tumor-morphologies into
dendritic morphologies. Rubenstein and Kaufman [49] have
developed a GGH model of avascular tumors with explicit
representation of two types of ECM fibers to study the effect of
ECM on growth of glioma spheroids in vitro. Rubenstein and
Kaufman showed that invasion is maximized at intermediate
collagen concentrations, as occurs experimentally.
In our simulations, the vascular structure produces inhomoge-
neities in oxygen tension on scales larger than those appearing in
continuum simulations depending on inhomogeneities in Extracel-
lular Matrix (ECM) and smaller than those due to tissue structure.
These inhomogeneities may affect tumor growth rates and
morphology and the somatic evolution of metastatic potential
within tumors. Thus, simulating vascular structure at the cell level is
crucial to developing biomedically-meaningful tumor simulations.
In this paper we simulate 3D solid tumor growth and angiogenesis
using the multi-cell GGH model. Our simulation omits many
biological details, but provides a useful starting point for the
construction of more realistic models. We focus on tumors where
the vasculature remains peripheral to the growing tumor. Our major
simplifications include: 1) We neglect the distinction between veins
and arteries, anastomosis, and the possible presence of pericytes and
smooth muscle cells. 2) Since oxygen-depleted areas of a tissue
coincide with nutrient-depleted and energy-depleted areas [50], we
assume that oxygen servesas the single limiting substrate field. 3) Cells
become hypoxic or necrotic by simple thresholding depending on the
local concentration of oxygen. 4) We neglect the basal metabolic
consumption of oxygen by tumor cells. 5) We assume that the oxygen
concentration in the capillaries is constant along the blood vessels,
neglecting vessel diameter, blood flow rate and vessel collapse due to
external pressure. 6) We assume that oxygen diffuses uniformly in the
host tissue and tumor. 7) We caricature the results of the hypoxic
signaling pathways as constant-rate secretion by hypoxic cells of a
single long-diffusion-length isoform of VEGF-A like VEGF-A121.8 )
Since we do not model blood flow explicitly, we neglect its
biomedically important effects on vascular remodeling and the
maturation of nascent blood vessels. 9) Rather than model tip-cell
selection explicitly, we distribute a certain number of inactive
neovascular c e l l s( t e r m si nb o l d ,e.g. neovascular, refer to specific
simulation classes), which behave identically to vascular cells until
the concentration of VEGF-A exceeds an activation threshold. 10)
We adopt the vascular-patterning hypothesis that activated vascular
endothelial cells secrete and chemotax towards a short-diffusion-
length chemoattractant (for a discussion of possible chemoattractant
candidates see [51,52]). 11) We employ a simplified model of tight
junctions between endothelial cells in the preexisting vasculature. 12)
We do not represent the ECM and the cells in the surrounding
normal tissue explicitly and neglect mechanisms related to ECM and
normal tissue remodeling, like secretion of ECM proteins by tumor
cells, secretion of ECM-degrading enzymes (matrix metalloproteinases),
and lactic acid accumulation.
Results
We ran otherwise identical simulations with and without
angiogenesis to study how tumor-induced vasculature affects
tumor growth and morphology. Figure 1 shows a time-series of
Simulation of Vascular Tumor
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exponentially for the first 10 days (Figure 2A and Figure 3A,
region 1 red); growth then slows and the tumor reaches a diameter
of about 200 mm (Figure 1B). Hypoxic domains form on day 8
(Figure 3C) and necrosis begins 12 hours later. The tumor grows
slowly and remains almost spherical until day 25 (Figure 3A,
region 2 red). At this stage, normal tumor cells form a layer of
maximum thickness 75 mm near blood vessels and no normal
cells persists far from the vasculature. The oxygen inhomogeneity
produces tumor protrusions towards the adjacent blood vessels.
Eventually the growing tumor pushes and stretches the vessels it
contacts, finally rupturing them on day 31 (see Movie S1 and
Figure 1C). At this stage, the tumor is large enough to span the
gaps between vessels and thus to access new vessels. This strategy
allows the tumor to grow at a moderate (Figure 3A, region 3 red)
rate throughout the 75 day simulation even without angiogenesis
and produce a cylindrical tumor with a diameter of about 200 mm
following the path of nearby blood vessels with normal cells only
present near blood vessels. This avascular tumor growth is
reminiscent of the first and second stages of growth of gliomas
[53] although glioma cells usually form a peripheral cluster
encompassing the blood vessel. (The growth and morphology of
the tumor after day 31 is an artifact of the simplified oxygen
transport in our model, see Discussion).
In simulations with angiogenesis, tumor growth resembles that
without angiogenesis for the first 15 days. Figure 4 shows the time
Figure 1. Time-series of simulated tumor growth without angiogenesis. A) Day 0: Pre-existing vasculature and the initial normal tumor cell
at: x=425 mm, y=425 mm, z=425 mm. B) Day 15: The tumor grows into a sphere with a maximum diameter of about 200 mm and remains at this size
from day 10 to day 25. C) Day 30: The tumor grows into a cylinder with a diameter of about 200 mm and a length of about 300 mm. The vasculature is
about to rupture. D) Day 75: The black arrow shows the location of the ruptured vessels. Cell types: Green: normal; yellow: hypoxic; blue: necrotic; red:
vascular; purple: neovascular. Axes are labeled in mm.
doi:10.1371/journal.pone.0007190.g001
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examples of both types of simulations. Growth is initially
exponential (3A, region 1 black). On day 8, hypoxic domains
form and start secreting VEGF-A (Figure 3C). VEGF-A reaches
and activates the nearest inactive neovascular cells a few hours
later. Activated neovascular cells then proliferate and chemotax
up the VEGF-A gradient. The elastic attachment of the initial
neovascular cells and contact inhibition of growth slow the cell-
cycle time of active neovascular cells in the preexisting
vasculature to *4 days (Figure 3C). Daughter neovascular cells
which lack elastic links and can have less contact with neighbors
have cell cycles of *1–2 days. The tumor does not grow
significantly from day 10 to day 14 when the first angiogenic
sproutsappear (Figure 3A,region2 black). Neovascular cells form
a connected peri-tumor network about 12 days after activation.
Figure 3Ashows that theinducedperi-tumor vasculature results ina
phase of linear tumor growth which we call the linear-spherical phase
(Figure 3A, region 3 black). During this phase, the tumor grows
linearly in volume, remaining spherical until itreaches a diameter of
about 300 mm onday18.Growththen slowsdrasticallyfromday18
to 25 (Figure 3A, region 4 black). After day 25 the larger tumor is
more sensitive to inhomogeneities in cell proliferation, initiating a
second phase of linear growth as tumor changes from spherical to
cylindrical (the linear-cylindrical phase, Figure 3A, region 5 black). This
change in shape can be interpreted as the growth of the mode with
the longest unstable wavelength which allows the tumor to grow
indefinitely as long as the peri-tumor vasculature covers the entire
tumor. By day 60, the cylindrical tumor has a bigger diameter than
that in the simulation without angiogenesis, with normal cells
distributed symmetrically about its axis. Positive feedback between
hypoxic cells and neovascular cells results in extensive growth of
neovascular cells. Neovascular cells self-organized into 2D
vascular sheets instead of 1D vascular branches at neovascular
densities higher than a critical density. These thicker branches
initiate a third phase of linear-sheet growth on day 60 (Figure 3A,
region 6) as the cylindrical tumor (Figure 2B) grows into a paddle-
like structure (Figure 4D).
Discussion
In general, tumors in our simulation are smaller than those
studied by Macklin et al. [26]. Macklin et al. found that avascular
tumors remained spherical during 45 days of simulated growth,
independent of the possible production or degradation of ECM. In
our simulations, the avascular tumors become more cylindrical
after day 25 and grow along (parallel to) the nearest blood vessel.
The models are sufficiently different that we cannot yet identify the
cause of this discrepancy. Both models produce similar growth
during the first 25 days and the hypoxic core forms about the same
time in both models (compare Figure 3A–C, region 2 and 3 red to
Figure 3 and 11 from [26]). In both our simualtions with
angiogenesis and Macklin et al. ’s (vascular growth simulation with
the effect of solid pressure-induced neovascular responce and
enhanced ECM degredation from [26]) the new vasculature
remains outside the tumor, which becomes elongated and paddle-
shaped. Vascular glioma tumors in Zheng et al. ’s model [28], like
avascular tumors in our model, show co-option behavior although
gliomas in their model breaks up into fragments and encompasses
newly formed blood vessels.
Our simulations assume that angiogenic sprouts can partially
support oxygen transport even before anastomosis. This assump-
tion affects tumor growth between days 15 and 20 when most
vascular sprouts have not formed closed loops. Requiring
anastomosis for oxygen transport would both delay the onset of
the vascular phase of tumor growth and make that growth more
rapid once it starts. Later in the simulation, most neovascular cells
form closed loops, so our simplification should have less effect.
Another artifact of our model of oxygen transport is that the tumor
in the simulation without angiogenesis grows to a size comparable
to the one in the simulation with angiogenesis, albeit more slowly.
Figure 2. Single-cell rendering of tumor cells. The green cells are normal tumor cells and the yellow cells are hypoxic cells. The preexisting
vasculature is rendered in red. A) Day 10: a spherical tumor without angiogenesis withnormal tumor cells only present near blood vessels. B) Day 60:
A cylindrical tumor with angiogenesis, diameter *300 mm and length *800 mm. The purple cells are active neovascular cells which are not rendered
individually. The white arrow indicates a vascular cell incorporated into a neovascular branch. Axes are labeled in mm.
doi:10.1371/journal.pone.0007190.g002
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cell proliferation exerts a force on the preexisting vasculature
which can stretch and even rupture vascular cords (Figure 1D,
Movie S1). Since we do not consider blood flow, such vascular
damage does not change Pvascular
blood (oxygen transport). If we
calculated blood flow, the tumor would stop growing on day 31,
then shrink slightly due to lack of oxygen. Vascular ruptures also
happen in the simulation with angiogenesis (Figure 2B), but
neovascular cells usually form new vessels to fill the gaps.
In reality, oxygen supply depends on blood vessel characteristics
like diameter and length. Because the production of O2 in our
simulations is proportional to the number of voxels in blood vessels,
more ECs supply more oxygen, regardless of their organization. For
example, formation of thick vascular cords and 2D vascular sheets in
the simulation with angiogenesis (Figure 1D, Movie S1) on day 60
initiates a phase of fast linear growth which is an artifact of our
simplified oxygen transport. Including the effects of vascular-network
connectivityanddepletionofoxygenalongthedirectionofbloodflow
would produce more realistic tumor growth and morphology.
In our simulations, the preexisting vasculature with an
average vascular branch length of about 300 mm supplies
oxygen initially. Vascular networks with shorter average
vascular branch lengths (keeping the average partial pressure
of oxygen the same) would produce larger solid tumors both with
and without angiogenesis. Since a tumor can grow to a
maximum diameter of 200 mm without angiogenesis, average
vascular branch lengths shorter than 200 mmw i l lp r o d u c e
infinitely long cylindrical solid tumors.
The random motility of normal and hypoxic cells within the
tumor also affects growth, reducing the inhomogeneities in cell
Figure 3. Growth curves for simulated tumors with (black) and without (red) angiogenesis. Black arrows: (1) the exponential growth
phase of the spherical tumor; (2) no growth; (3) the linear-spherical phase; (4) slow growth; (5) the linear-cylindrical phase; (6) the linear-sheet phase.
Red Arrows: (1) the exponential growth phase of the spherical tumor; (2) slow growth; (3) cylindrical growth phase. A) The number of live tumor cells
(normal and hypoxic) during 75 days of simulated tumor growth with and without angiogenesis. B) Development of the number of normal tumor
cells vs. time. C) The number of hypoxic tumor cells vs. time. D) The number of neovascular cells in the simulation with angiogenesis vs. time.
doi:10.1371/journal.pone.0007190.g003
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cell motilities paradoxically arrest tumor growth at diameters of
200 mm (no angiogenesis) and 300 mm (with angiogenesis) (data not
shown). In contrast, lower cell motilities enhance formation of fingers
and nodules which increase the invasiveness of the solid tumor. In
reality, motility also depends on the adhesiveness of cellsto eachother
and to the ECM, so this effect may not be clinically relevant.
We also assume that the vasculature remains peripheral to the
tumor. Formation of blood vessels inside the tumor enhances
oxygen transport and allows arbitrarily large tumors and faster,
though not necessarily more invasive, growth.
Tumor growth in real tissues leads to increasing hydrostatic and
solid pressures, inducing tumor-cell quiescence and necrosis and
also causing blood vessels to collapse. Because ECM in our
simulation is not confined by physical boundaries and does not have
a volume constraint, the pressure in our tumor does not change due
to tumor growth. Explicitly modeling the cells and ECM in the peri-
tumor region would result in a more realistic pressure.
Our simplified tumor induces angiogenesis through VEGF signaling,
but neglects other tumor-induced changes in the surrounding
vasculature, including apoptosis of endothelial cells because of reduced
pericyte coverage and lowered pH. Combining these vascular
remodeling mechanisms with blood-flow calculations would give further
insight into the effects of angiogenesis on vascular tumor growth.
Although our high-resolution simulation represents a fairly
small tissue volume, our results can scale to treat larger tissue
volumes at lower spatial resolution. Such scaling tradeoffs may be
useful for simulating tumors like prostate cancer, which involve
multiyear progressions and centimeter-scale tissues.
A realsolid tumor with a volume of about 1 cm3 typically has 108
cells. Our current version of CompuCell3D (see Implementation
Parameters and Initial Conditions) can simulate 75 days of growth
Figure 4. Time-series of tumor growth with angiogenesis. A) Day 0: The pre-existing vasculature and the initial normal tumor cell. B) Day 15:
The tumor grows into a sphere with a maximum diameter of about 300 mm. The purple cells are active neovascular cells. C) Day 30: The tumor grows
into a cylinder with a length of about 350 mm and a diameter of about 300 mm. The vasculature is about to rupture. D) Day 75: The developed
vascularized tumor. The white arrow-head shows neovascular cells organized into 2D sheets. Cell types: Green: normal; yellow: hypoxic; blue: necrotic;
red: vascular; purple: neovascular. Axes are labeled in mm.
doi:10.1371/journal.pone.0007190.g004
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To simulate more realistic tumors without needing to treat cluster of
cells as single generalized cells, we are investigating parallel
computation techniques. Chen et al. [54] have developed a
Message Passing Interface Standard (MPI) parallel implementation
of the GGH which permits simulations with more than 107 cells.
Currently, we are developing a parallel implementation of
CompuCell3D to take advantage of multi-core processors with
shared memory and graphics processing units. The new version of
CompuCell3D willbe able to simulatemore than 107 cellsin7 days.
Our next extension of these simulations will include blood flow
to improve our description of substrate transport and also include
shear effects on vascular remodeling.
Methods
The Glazier-Graner-Hogeweg Model
Our simulation uses the Glazier-Graner-Hogeweg model (GGH,
also known as the Cellular Potts Model, CPM), a multi-cell, lattice-
based, stochastic model which describes biological cells and their
interactions in terms of Effective Energies and constraints. GGH
applications include modeling avascular tumor growth [47,49],
biofilms [55], chick limb growth [56], somitogenesis [57], blood
flow and thrombus development [58] and angiogenesis [51,59–
61]. Each cell consists of a domain in a cell lattice of lattice sites,o r
voxels, at locations~ i i, sharing the same cell index, s. Each cell has an
associated cell type, t. The Effective Energy governs changes in the cell
configuration. The basic Effective Energy describes constant-volume
cells interacting via differential adhesion:
HGGH~
P
~ i i,~ j j neighbors
J ts ~ i i
     
,ts~ j j
        
1{ds ~ i i
  
,s ~ j j
        
z
P
s
lVol t ðÞv s ðÞ {Vt ts ðÞ ðÞ ðÞ
2,
ð1Þ
where v s ðÞis the total number of lattice sites in cell s, which is
constrained to be close to the target volume Vt (i.e., deviation of
v s ðÞfrom Vt ts ðÞ ðÞ increases the Effective Energy), and lVol is the
inverse compressibility of cells of type t. J ts ~ i i
     
,ts~ j j
        
is the
contact energy per unit area between cells s ~ i i
  
and s ~ j j
  
.
2lVol Vt{v s ðÞ ðÞ is the internal pressure in cell s. To simulate the
cytoskeletally-driven reorganization of cells and tissues, we model
cell protrusions and retractions using a modified Metropolis dynamics.
For each attempt of a cell to displace a neighbor, we select at
random a cell boundary (source voxel) and a neighboring target voxel
and calculate the change in the effective energy DH, if the source
cell displaced the target cell at that voxel. If DH is negative, i.e., the
change is energetically favorable, we make it. If DH is positive, we
accept the change with probability e{DH=T, where T describes the
amplitude of cytoskeletal fluctuations. On a lattice with N sites, N
displacement attempts represent our basic unit of time, one Monte
Carlo Step (MCS). We describe secreted morphogens and oxygen
macroscopically by concentration fields discretized at the
resolution of the cell lattice. Fields evolve according to simple
time-dependent partial-differential equations (PDEs). In addition
to contact and volume energies, we include a chemotaxis term in
the Effective Energy to model angiogenesis (see below).
We define a special, generalized cell representing the extracel-
lular medium (ECM). The total volume and surface area of ECM
are not constrained. ECM voxels can be both source voxels, e.g.
during retraction of the trailing-edge of a cell, and target voxels,
e.g. during formation of lamellipodia. Since ECM does not have
cytoskeletal fluctuations, we use the amplitude of cytoskeletal
fluctuations of the target or source cell to determine the
acceptance of the displacement.
Our model contains three tumor-cell types: normal, hypoxic
and necrotic (we use the designation tumor cell to refer to both
normal and hypoxic cells). Normal tumor cells become
hypoxic when the oxygen partial pressure (pO2) is less than
5 mmHg [22,50,62] and become necrotic when pO2 drops
below 1 mmHg. Normal and hypoxic cells take up oxygen (see
below) and proliferate at a rate which depends on the oxygen
partial pressure according to a Michaelis-Menten form. To model
tumor cell proliferation, we increase the cell’s target volume
according to:
dVt tumor ðÞ
dt
~
GmpO2 ~ i i
  
O0zpO2 ~ i i
   , ð2Þ
where pO2 ~ i i
  
is the pO2 at the center-of-mass of the cell. We
discuss the maximum growth rate, Gm, in the next section. When a
cell’s volume reaches its doubling volume, we split the cell along the
x–y plane. The two daughter cells receive equal target volumes of
half of the target volume of the mother cell at mitosis. Necrotic
cells lose volume at a constant rate:
dVt necrotic ðÞ
dt
~{kn: ð3Þ
We remove zero-volume cells. Hypoxic cells secrete the
field V ~ i i
  
, which models the pro-angiogenic factor VEGF-A.
Hypoxic cells stop secreting VEGF-A and become normal if
pO2 is above 5 mmHg and become necrotic if pO2 drops below
1 mmHg. Hypoxic cells secrete V ~ i i
  
at a constant normalized
rate aV~1 per MCS at each voxel in their volume. V ~ i i
  
diffuses
with diffusion constant DV and decays at a rate [V,s oV ~ i i
  
evolves according to:
LV
Lt
~{[V Vzdts~ x x ðÞ ðÞ ,hypoxic ðÞ aV VzDV+2V, ð4Þ
where dts~ x x ðÞ ðÞ ,hypoxic ðÞ ~1 at voxels belong to hypoxic cells
and ~0 elsewhere. Since cell motility is large, cells diffuse and
rearrange fast enough to prevent artifacts due to their fixed
cleavage plane [47].
Our model also contains two basic endothelial cell (EC)
types: vascular and neovascular. We further distinguish two
types of neovascular cells, inactive neovascular and active
neovascular. Vascular cells build the preexisting mature
vasculature. To represent tight junctions between endothelial cells
in mature capillaries which maintain the integrity of blood vessels,
linear springs connect the centers-of-mass of vascular cells. The
springs obey the elastic constraint, Eelastic~lelastic l{lt ðÞ
2, where lt
is the equilibrium length of the connection and l is the distance
between the two neighbors. To model vascular rupture we set
lelastic~0 between the two neighbors when l between the two
neighbors is greater than lmax. Inactive neovascular cells
behave exactly like vascular cells. However, above a threshold
value V0 of V ~ i i
  
inactive neovascular cells switch irreversibly
into active neovascular cells. Active neovascular cells can
proliferate and chemotax up gradients of VEGF-A. To account for
the contact-inhibited growth of neovascular cells, when the
common surface area with other vascular, inactive neovas-
cular and active neovascular cells is less than a threshold, we
increase the target volume of the active neovascular cells
Simulation of Vascular Tumor
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dVt neovacular ðÞ
dt
~
GvV ~ i i
  
nV 0zV ~ i i
   , ð5Þ
where V ~ i i
  
is the concentration of VEGF-A at the center-of-mass
of the cell and n is a scaling constant describing the proportionality
of the activation concentration to the concentration at which the
growth rate is half its maximum. Active neovascular cells divide
along the x–y plane when their volume reaches a specified doubling
volume. After mitosis, both daughter cells are active neovascular
and inherit half of their mother’s target volume. Active
neovascular cells at the tip of a sprout share two features with
real tip-cells: 1) Compared to stalk cells, they have more free
boundary which can respond to gradients of VEGF-A, dragging
the rest of the sprout up the gradients. 2) Dragging reduces the
contact area between active neovascular cells, promoting
neovascular growth. Unlike real tip-cells, active neovascular
cells at the tip of a sprout proliferate. Thus sprouts grow faster in
steeper gradients of VEGF-A as long as the concentration of
VEGF-A is well below the saturation concentration. We add a
saturated Savil-Hogeweg-type chemotaxis term with contact
inhibition to the basic DH of the Effective Energy to represent
the net effect of preferential formation of pseudopods in response
to the gradient of the chemoattractant field near the active
neovascular cell’s boundary [63]:
DHchemotaxis~ ms target
  
{ms source ðÞ
  
V ~ i itarget
  
sV0zV ~ i itarget
   {
V ~ i isource
  
sV0zV ~ i isource
  
 !
,
ð6Þ
DHchemotaxis~0a tE C {EC boundaries, ð7Þ
DHtotal~DHchemotaxiszDHGGH, ð8Þ
where m is the degree of chemotactic response of the cell and s is a
positive number which scales the VEGF-A concentration field
relative to the neovascular activation threshold. m ECM ðÞ ~0.
Growth and chemotaxis of active neovascular cells up
gradients of VEGF-A produce a dispersed growing population of
neovascular cells rather than a connected capillary network [51].
To self-organize vascular and neovascular cells into a capillary-
like structure we extended to 3D Merks’ 2D model of angiogenesis
in which endothelial cells self-organize into capillary-like networks
in response to autocrine chemotaxis to a very short-diffusing
chemoattractant [51]. We denote this chemoattractant field by
C ~ i i
  
. Vascular and neovascularcells secrete itata constant rate
aC at all their voxels, the chemoattractant degrades at a constant
rate [C in the ECM, and diffuses at a constant rate DC everywhere:
LC
Lt
~aC dts~ x x ðÞ ðÞ ,EC ðÞ {[C C 1{dts~ x x ðÞ ðÞ ,EC ðÞ ðÞ
zDC+2C,
ð9Þ
where dts~ x x ðÞ ðÞ ,EC ðÞ ~1 inside vascular and neovascular cells
and ~0 elsewhere. Both vascular and neovascular cells in our
model chemotax up gradients of C ~ i i
  
. We include a linear version
of eq. 8 [51] to model contact-inhibited chemotaxis:
DHchemotaxis~ ms target
  
{ms source ðÞ
  
V ~ i itarget
  
{V ~ i isource
     
,
ð10Þ
DHchemotaxis~0a tE C {EC boundaries, ð11Þ
DHtotal~DHchemotaxiszDHGGH: ð12Þ
Autocrine chemotaxis produces a capillary-like structure, while the
elastic constraint between vascular cells makes the preexisting
vasculature more stable and less flexible.
Vasculature transports oxygen to the host tissue and the tumor.
We represent the oxygen partial pressure, pO2,b yafield P ~ i i
  
.
Since we initialize our simulations with a fully anastomosed
preexisting vasculature and since not all neovascular cells form
in closed loops, we assume that the oxygen partial pressure in the
preexisting capillaries, Pvascular
blood , is higher than Pneovascular
blood in the
tumor-induced vasculature (see [64,65], for more accurate blood-
flow calculations). We assume that the oxygen field concentration
neighboring a vessel changes proportionally to pO2 according to a
solubility coefficient, O2~KOP ~ i i
  
. Available O2 diffuses at a
constant rate DO in the surrounding tissue and is consumed by
tumor cells. Since oxygen consumption of human cells is almost
constant until pO2 drops below 0.5–1 mmHg and the consump-
tion rate is constant below this pressure, we use a piecewise-linear
approximation of Michaelis-Menten kinetics to model oxygen
consumption. Tumor cells take up oxygen at a rate proportional
to P ~ i i
  
with a maximum rate of Otumor
max . The cells near the
vasculature consume oxygen at their maximum rate, but cells far
from the vasculature have growth limited by the available oxygen
and take up oxygen at a rate [tumor
O P. To represent oxygen
consumption by host cells in the normal tissue, which we do not
model explicitly, we assume an oxygen consumption rate of
[tissue
O P saturating at a maximum rate of Otissue
max in the ECM. We
include oxygen consumption by EC cells in the adjusted oxygen
partial pressure. Thus oxygen evolves according to:
LP
Lt
~{min [tissue
O P,Otissue
max
  
1{dts~ x x ðÞ ðÞ ,ECM ðÞ ðÞ
{min [tumor
O P, Otumor
max
  
dts~ x x ðÞ ðÞ ,tumor ðÞ zKODO+2P,
ð13Þ
P ~ x x ðÞ ~Pvascular
blood dts~ x x ðÞ ðÞ ,vascular ðÞ
zPneovascular
blood dts~ x x ðÞ ðÞ ,neovascular ðÞ ,
ð14Þ
where dts~ x x ðÞ ðÞ ,vascular ðÞ ~1 and dts~ x x ðÞ ðÞ ,neovascular ðÞ ~1
inside vascular and neovascular cells and dts~ x x ðÞ ðÞ , ð
tumorÞ~1 while dts~ x x ðÞ ðÞ ,tumor ðÞ ~1 and dts~ x x ðÞ ðÞ , ð
tumorÞ~0 elsewhere. [tumor
O is the oxygen consumption rate for
both normal and hypoxic cells. We have summarized the
properties of the fields in Table 1 and cell types and their
behaviors in Table 2.
Implementation Parameters and Initial Conditions
Our simulations use the open-source CompuCell3D simulation
environment (http://www.compucell3d.org/) [66]. We ran our
simulation on a 180|180|180 lattice with periodic boundary
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represents a tissue with a volume of 0:9|0:9|0:9 mm3. Our
average simulated tumor cell has a volume of about 27 voxels or
3375 mm3. We stored the cell-lattice configuration every 3
simulated hours and rendered each snapshot using the MATLAB
volume-visualization functions (Our group is integrating post-
rendering capabilities into CompuCell3D). Since rendering indi-
vidual cells is computationally expensive, in Figures 1 and 4 and
Supplemental Movies (Movie S1 and S2) we have only rendered
boundaries between cells which differ in type. For demonstration
purposes, we have rendered the boundaries of individual tumor
cells in the simulation with angiogenesis on day 60 (Figure 2B) and
in the simulation without angiogenesis on day 10 (Figure 2A).
Experimentally, tumor cells from lines such as U-87 human
glioma [67–70] can move at a rate of about 0.35 mm/min. For
typical parameter settings in our simulations tumor cells move at
about 0.1 pixels/MCS. Equating the experimental and simulated
mean cell speeds implies 1000 MCS *24 h.
We start our simulation with a single normal tumor cell near the
center of the cell lattice and a preexisting network of blood vessels
(see Figure 1). We assume that Pvascular
blood ~90 mmHg in the
preexisting vasculature and Pneovascular
blood ~50 mmHg in the tumor-
induced vasculature. We set the diffusion constant of oxygen in our
simulations to 103 mm2/s, about half its diffusion constant in water.
Since hypoxic cells in our simulations become necrotic if P ~ i i
  
drops below 1 mmHg, we set both [tissue
O and [tumor
O to 1. We set
Otissue
max so the average P ~ i i
  
of the tissue reaches an asymptotic value
of 20 mmHg. We assume that the density of cells in the tumor is
about 10 times the density of the cells distributed in the ECM
(which we do not represent explicitly). We assume that both
hypoxic and normal tumor cells in our model consume oxygen at
a rate up to 3 times that of the cells in the surrounding tissue, thus
Otumor
max = 3|10| Otissue
max . Higher oxygen consumption results in
shorter oxygen penetration lengths and smaller solid tumors. We set
O0~10 mmHg and choose Gm so that the cell cycle of tumor cells
at P ~ i i
  
~25 is 24 h. For these parameters our simulations produce
solid tumors with maximum diameters of 200 mm.
Experimentally, the VEGF-A diffusion constant is about
10 mm2/s in typical tissues and its decay rate is about 0.65 h{1
[52]. We set the activation VEGF-A concentration V0 =0.5,
s~1,a n dp i c kGV so that a neovascular cell that does not
contact any vascular or neovacular cells has a minimum
cell-cycle time of 24 h. Due to contact-inhibition of growth,
neovascular cells incorporated in a tumor-induced vessel
grow at a negligible rate.
We assume that integrins are down-regulated in tumor cells and
that cell-cell adhesion via cadherins keeps the tumor solid, i.e. that
the surface tension at the tumor-ECM interface is positive,
J tumor,tumor ðÞ v2J tumor,ECM ðÞ (for definitions of surface
tensions see [44,45]). We set a positive surface tension between
EC (vascular and neovascular) and tumor cells (J tumor, ð
ECMÞzJ EC,ECM ðÞ vJ tumor,EC ðÞ ) which keeps the vasculature
peripheral to the tumor. For the specific values of J and the other
parameters, see the supplemental XML and python files (Code S1).
Table 1. Diffusive molecules in the vascular tumor-growth
simulation.
Fields Definition Role/Properties
P ~ i i
  
partial pressure
of oxygen
-regulates tumor cell growth
-induces normal < hypoxic transition
-induces hypoxic ? necrotic transition
V ~ i i
  
long-diffusing
proangiogenic
factor
-hypoxic signaling
-induces inactive neovascular ? active neovascular
transition
-regulates neovascular growth
-chemoattractant for vascular and neovascular cells
C ~ i i
  
short-diffusing
chemoattractant
-self-organizes vascular and neovascular cells into
capillary networks
-chemoattractant for vascular and neovascular cells
All molecules diffuse everywhere uniformly and isotropically. Boundary
conditions of the lattice are periodic.
doi:10.1371/journal.pone.0007190.t001
Table 2. Cell types in the simulations and their behaviors.
Cells Behaviors
Tumor cells
Normal -proliferate
-consume oxygen
-change to hypoxic
-change to necrotic
Hypoxic -proliferate
-consume oxygen field
-change to normal
-change to necrotic
-secrete long-diffusing proangiogenic field V ~ i i
  
Necrotic -shrink
-disappear
Endothelial cells
Vascular -consume oxygen field
-supply oxygen field at partial pressure Pvascular
blood
-secrete short-diffusing chemoattractant field C ~ i i
  
-chemotax up gradients of field C ~ i i
  
-elastically connect to neighboring
vascular and inactive neovascular cells
-lose elastic connections, when lwlmax
Inactive neovascular -consume oxygen field
-supply oxygen field at partial pressure Pvascular
blood
-secrete short-diffusing chemoattractant field C ~ i i
  
-chemotax up gradients of field C ~ i i
  
-elastically connect to neighboring
vascular and inactive neovascular cells
-lose elastic connections, when lwlmax
-change to active neovascular
Active neovascular -consume oxygen field
-supply oxygen field at partial pressure Pneovascular
blood
-secrete short-diffusing chemoattractant field C ~ i i
  
-chemotax up gradients of field C ~ i i
  
-chemotax up gradients of field V ~ i i
  
-proliferate
doi:10.1371/journal.pone.0007190.t002
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Code S1 XML configuration and python scripts of the
simulation with angiogenesis.
Found at: doi:10.1371/journal.pone.0007190.s001 (0.27 MB ZIP)
Movie S1 Initially, the tumor grows exponentially and reaches a
maximum diameter of about 200 micrometers. The growing
cylindrical tumor pushes and stretches the vessels it contacts,
finally rupturing them on day 31. Total movie time=75 days.
Time interval between frames=6 hours. The camera rotates at a
rate of 0.1 degree per frame. Cell types: Green: normal; yellow:
hypoxic; blue: necrotic; red: vascular. Axes are labeled in
micrometer.
Found at: doi:10.1371/journal.pone.0007190.s002 (9.96 MB AVI)
Movie S2 Initially, the tumor grows exponentially. When
oxygen level drops below a threshold, the normal tumor cells
become hypoxic and start secreting a long-diffusing proangiogenic
factor. At this stage, the tumor reaches a maximum diameter of
about 300 micrometers. The activated neovascular cells in the pre-
existing vasculature respond to the pro-angiogenic factors both by
chemotaxing towards higher concentrations of the proangiogenic
field and by forming new blood vessels via angiogenesis. The
tumor-induced neovascular network enhances oxygen supply and
tumor growth. Total movie time=75 days. Time interval between
frames=6 hours. The camera rotates at a rate of 0.1 degree per
frame. Cell types: Green: normal; yellow: hypoxic; blue: necrotic;
red: vascular; purple: neovascular. Axes are labeled in micrometer.
Found at: doi:10.1371/journal.pone.0007190.s003 (9.71 MB AVI)
Author Contributions
Conceived and designed the experiments: AS JG. Analyzed the data: AS
JG. Wrote the paper: AS JSG JG. Helped with coding: BLZ NJP MS.
References
1. deWaal RMW, Leenders WPJ (2005) Sprouting angiogenesis versus co-option in
tumor angiogenesis. In: Clauss M, Breier G, eds. Mechanisms of Angiogenesis,
Birkhauser Verlag/Switzerland. pp 65–76.
2. Marti HH (2005) Angiogenesis - a self adapting principle in hypoxia. In:
Clauss M, Breier G, eds. Mechanisms of Angiogenesis, Birkhauser Verlag/
Switzerland. pp 163–180.
3. Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and
escape mechanisms. Nat Rev Cancer 3: 362–374.
4. Shima DT, Adamis, Ferrara N, Yeo KT, Yeo T, et al. (1995) Hypoxic induction
of endothelial growth factors in retinal cells: identification of vascular endothelial
growth factor (VEGF) as the mitogen. Molecular Medicine 1: 182–193.
5. Carmeliet P (2001) Cardiovascular biology. Creating unique blood vessels.
Nature 412: 868–869.
6. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other
disease. Nature Med 1: 27–31.
7. Folkman J, D’Amore PA (1996) Blood vessel formation: what is its molecular
basis? Cell 87: 1153–1155.
8. Jiang BH, Semenza GL, Bauer C, Marti HH (1996) Hypoxia-inducible factor 1
levels vary exponentially over a physiologically relevant range of O2 tension.
Am J Physiol 271: C1172–C1180.
9. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, et al. (2001) Induction
of HIF-1a in response to hypoxia is instantaneous. FASEB J 15: 1312–1314.
10. Wenger RH (2002) Cellular adaptation to hypoxia: O2-sensing protein
hydroxylases, hypoxia-inducible transcription factors, and o2-regulated gene
expression. FASEB J 16: 1151–1162.
11. Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial
growth factor (VEGF) and their receptors. J Cell Sci 114: 853–865.
12. Kusters B, de Waal RM, Wesseling P, Verrijp K, Maass C, et al. (2003)
Differential effects of vascular endothelial growth factor A isoforms in a mouse
brain metastasis model of human melanoma. Cancer Res 63: 5408–5413.
13. Gerhardt H (2008) VEGF and endothelial guidance in angiogenic sprouting.
Organogenesis 4: 241–246.
14. Phng LK, Gerhardt H (2009) Angiogenesis: a team effort coordinated by notch.
Dev Cell 16: 196–208.
15. Jurasz P, Alonso D, Castro-Blanco S, Murad F, Radomski MW (2003)
Generation and role of angiostatin in human platelets. Blood 102: 3217–3223.
16. Wallez Y, Huber P (2008) Endothelial adherens and tight junctions in vascular
homeostasis, inflammation and angiogenesis. Biochim Biophys Acta 1778:
794–809.
17. Dejana E, Corada M, Lampugnani MG (1995) Endothelial cell-to-cell junctions.
FASEB J 9: 910–918.
18. Perryn ED, Cziro ´k A, Little CD (2003) Vascular sprout formation entails tissue
deformations and VE-cadherin-dependent cell-autonomous motility. Dev Biol
2008: 545–555.
19. Lampugnani MG, Zanetti A, Corada M, Takahashi T, Balconi G, et al. (2003)
Contact inhibition of VEGF-induced proliferation requires vascular endothelial
cadherin, b-catenin, and the phosphatase DEP-1/CD148. J Cell Biol 161:
793–804.
20. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653–660.
21. Dor Y, Djonov V, Keshet E (2003) Making vascular networks in the adult:
branching morphogenesis without a roadmap. Trends Cell Biol 13: 131–136.
22. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature
407: 249–257.
23. Sanga S, Frieboes HB, Zheng X, Gatenby R, Bearer EL, et al. (2007) Predictive
oncology: a review of multidisciplinary, multiscale in silico modeling linking
phenotype, morphology and growth. Neuroimage 37: 120–134.
24. Anderson ARA, Chaplain MAJ (1998) Continuous and discrete mathematical
models of tumour-induced angiogenesis. Bull Math Biol 60: 857–899.
25. Alarco ´n T, Byrne HM, Maini PK (2004) Towards whole-organ modelling of
tumour growth. Prog Biophys Mol Biol 85: 451–472.
26. Macklin P, McDougall S, Anderson AR, Chaplain MA, Cristini V, et al. (2009)
Multiscale modelling and nonlinear simulation of vascular tumour growth.
J Math Biol 58: 765–798.
27. Mantzaris NV, Webb S, Othmer HG (2004) Mathematical modeling of tumor-
induced angiogenesis. J Math Biol 49: 111–187.
28. Zheng X, Wise SM, Cristini V (2005) Nonlinear simulation of tumor necrosis,
neo-vascularization and tissue invasion via an adaptive finite-element/level-set
method. Bull Math Biol 67: 211–259.
29. Frieboes HB, Lowengrub JS, Wise S, Zheng X, Macklin P, et al. (2007)
Computer simulation of glioma growt and morphology. Neuroimage 37: 59–70.
30. Plank MJ, Sleeman BD (2004) Lattice and non-lattice models of tumour
angiogenesis. Bull Math Biol 66: 1785–1819.
31. Cristini V, Li X, Lowengrub JS, Wise SM (2009) Nonlinear simulations of solid
tumor growth using a mixture model: invasion and branching. J Math Biol 58:
723–763.
32. Owen MR, Alarcon T, Maini PK, Byrne HM (2009) Angiogenesis and vascular
remodelling in normal and cancerous tissues. Math Biol 58: 689–721.
33. Alarcon T, Byrne MH, Maini PK (2005) A multiple scale model for tumor
growth. Multiscale Model Simul 3: 440–475.
34. Bartha K, Rieger H (2006) Vascular network remodeling via vessel cooption,
regression and growth in tumors. J Theor Biol 241: 903–918.
35. Welter M, Bartha K, Rieger H (2008) Emergent vascular network inhomoge-
neities and resulting blood flow patterns in a growing tumor. J Theor Biol 250:
257–280.
36. McDougall SR, Anderson AR, Chaplain MA (2006) Mathematical modelling of
dynamic adaptive tumour-induced angiogenesis: clinical implications and
therapeutic targeting strategies. J Theor Biol 241: 564–589.
37. Stephanou A, McDougall SR, Anderson ARA (2006) Mathematical modelling of
the influence of blood rheological properties upon adaptative tumour-induced
angiogenesis. Math Comput Model 44: 96–123.
38. Stephanou A, McDougall SR, Anderson ARA (2005) Mathematical modelling of
flow in 2 d and 3 d vascular networks: Applications to anti-angiogenic and
chemotherapeutic drug strategies. Math Comput Model 41: 1137–1156.
39. Pries AR, Secomb TW, Gaehtgens P (1996) Biophysical aspects of blood flow in
the microvasculature. Cardiovasc Res 32: 654–67.
40. Pries AR, Secomb TW (2005) Control of blood vessel structure: insights from
theoretical models. Am J Physiol Heart Circ Physiol 288: 1010–1015.
41. Pries AR, Secomb TW (2008) Modeling structural adaptation of microcircu-
lation. Microcirculation 15: 753–764.
42. Pries AR, Cornelissen AJ, Sloot AA, Hinkeldey M, Dreher MR, et al. (2009)
Structural adaptation and heterogeneity of normal and tumor microvascular
networks. PLoS Comput Biol 5: e1000394.
43. Ramis-Conde I, Chaplain MA, Anderson AR, Drasdo D (2009) Multi-scale
modelling of cancer cell intravasation: the role of cadherins in metastasis. Phys
Biol 6: 16008.
44. Graner F, Glazier JA (1992) Simulation of biological cell sorting using a two-
dimensional extended Potts model. Phys Rev Lett 69: 2013–2016.
45. Glazier JA, Graner F (1993) Simulation of the differential adhesion driven
rearrangement of biological cells. Phys Rev E 47: 2128–2154.
46. Glazier JA, Balter A, Poplawski NJ (2007) Magnetization to morphogenesis: a
brief history of the Glazier-Graner-Hogeweg model. In: (Anderson AR,
Chaplain MAJ, Rejniak KA, eds. Single-Cell-Based Models in Biology and
Medicine, Birkha ¨user/Verlag. pp 79–106.
47. Poplawski NJ, Agero U, Gens JS, Swat M, Glazier JA, et al. (2009) Front
instabilities and invasiveness of simulated avascular tumors. Bull Math Biol 71:
1189–1227.
Simulation of Vascular Tumor
PLoS ONE | www.plosone.org 10 October 2009 | Volume 4 | Issue 10 | e719048. Anderson ARA (2005) A hybrid mathematical model of solid tumour invasion:
the importance of cell adhesion. Math Med Biol 22: 163.
49. Rubenstein BM, Kaufman LJ (2008) The role of extracellular matrix in glioma
invasion: a cellular Potts model approach. Biophys J 95: 5661–5680.
50. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient
supply, and metabolic microenvironment of human tumors: a review. Cancer
Res 49: 6449–65.
51. Merks RMH, Perryn ED, Shirinifard A, Glazier JA (2008) Contact-inhibited
chemotaxis in de novo and sprouting blood-vessel growth. PLoS Comput Biol 4:
e1000163.
52. Serini G, Ambrosi D, Giraudo E, Gamba A, Preziosi L, et al. (2003) Modeling
the early stages of vascular network assembly. EMBO J 22: 1771–1779.
53. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005) Angiogenesis in
gliomas: biology and molecular pathophysiology. Brain Pathol 15: 297–310.
54. Chen N, Glazier JA, Izaguirre JA, Alber MS (2007) A parallel implementation of
the Cellular Potts model for simulation of cell-based morphogenesis. Comput
Phys Commun 176: 670–681.
55. Poplawski NJ, Shirinifard A, Swat M, Glazier JA (2008) Simulation of single-
species bacterial-biofilm growth using the Glazier-Graner-Hogeweg model and
the CompuCell3D modeling environment. Math Biosci Eng 5: 355–388.
56. Poplawski NJ, Swat M, Gens JS, Glazier JA (2007) Adhesion between cells,
diffusion of growth factors, and elasticity of the AER produce the paddle shape
of the chick limb. Physica A 373: 521–532.
57. Glazier JA, Zhang Y, Swat M, Zaitlen B, Schnell S (2008) Coordinated action of
n-cam, n-cadherin, epha4, and ephrinb2 translates genetic prepatterns into
structure during somitogenesis in chick. Curr Top Dev Biol 81: 205–247.
58. Xu Z, Chen N, Shadden SC, Marsden JE, Kamocka MM, et al. (2009) Study of
blood flow impact on growth of thrombi using a multiscale model. Soft Matter 5:
769–779.
59. Merks RMH, Glazier JA (2006) Dynamic mechanisms of blood vessel growth.
Nonlinearity 19: 1–10.
60. Bauer AL, Jackson TL, Jiang Y (2009) Topography of extracellular matrix
mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS
Comput Biol 5: e1000445.
61. Bauer AL, Jackson TL, Jiang Y (2007) A cell-based model exhibiting branching
and anastomosis during tumor-induced angiogenesis. Biophys J 92: 3105–3121.
62. Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2
gradients in solid tumors in vivo: high-resolution measurements reveal a lack of
correlation. Nature Med 3: 177–182.
63. Balter A, Merks RMH, Poplawski NJ, Swat M, Glazier JA (2007) The Glazier-
Graner-Hogeweg model: extensions, future directions, and opportunities for
further study. In: Anderson AR, Chaplain MAJ, Rejniak KA, eds. Single-Cell-
Based Models in Biology and Medicine, Birkha ¨user/Verlag,. pp 151–167.
64. Chaplain MA, McDougall SR, Anderson AR (2006) Mathematical modeling of
tumor-induced angiogenesis. Annu Rev Biomed Eng 8: 233–257.
65. Popel AS (1989) Theory of oxygen transport to tissue. Crit Rev Biomed Eng 17:
257–321.
66. Swat MH, Hester SD, Balter AI, Heiland RW, Zaitlen BL, et al. (2009) Multicell
simulations of development and disease using the compucell3d simulation
environment. Methods Mol Biol 500: 361–428.
67. Fotos JS, Patel VP, Karin NJ, Temburni MK, Koh JT, et al. (2006) Automated
time-lapse microscopy and high-resolution tracking of cell migration. Cytotech-
nology 51: 7–19.
68. Bray D (1992) Cell Movements. New York: Garland Publishing.
69. Sander LM, Deisboeck TS (2002) Growth patterns of microscopic brain tumors.
Phys Rev E 66: 051901.
70. Burgess PK, Kulesa PM, Murray JD, Alvord EC (1997) The interaction of
growth rates and diffusion coefficients in a three-dimensional mathematical
model of gliomas. J Neuropathol Exp Neurol 56: 704–713.
Simulation of Vascular Tumor
PLoS ONE | www.plosone.org 11 October 2009 | Volume 4 | Issue 10 | e7190